Global Peptide-Drug Conjugates(PDCs) CDMO Service Supply, Demand and Key Producers, 2024-2030

Page: 129

Published Date: 11 Oct 2024

Category: Medical Care

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags

Description

Peptide-drug conjugates (PDCs) consist of a cytotoxic payload, a homing peptide, and a linker between the peptide and the cytotoxic payload. Following antibody-drug conjugates, they are the next generation of targeted therapeutics with enhanced cell permeability and better drug selectivity. They offer excellent opportunities for targeting cancer, metabolic diseases, and more. Although the potential is huge, development challenges such as poor stability, poor targeting, and potential payload toxicity may slow down preclinical and clinical development processes. CDMO services refer to pharmaceutical companies and biotechnology companies outsourcing the research and development and production of their drugs or biologics to professional CDMO companies. These CDMO companies provide a range of services, including but not limited to drug synthesis, chemical and biological analysis, formulation development, clinical production, and commercial production. The core of CDMO services lies in its customization and specialization capabilities, which can meet the specific needs of different customers at different stages.

The global Peptide-Drug Conjugates(PDCs) CDMO Service market size is expected to reach $ million by 2030, rising at a market growth of %CAGR during the forecast period (2024-2030).

This report studies the global Peptide-Drug Conjugates(PDCs) CDMO Service demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Peptide-Drug Conjugates(PDCs) CDMO Service, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2023 as the base year. This report explores demand trends and competition, as well as details the characteristics of Peptide-Drug Conjugates(PDCs) CDMO Service that contribute to its increasing demand across many markets.

Highlights and key features of the study
Global Peptide-Drug Conjugates(PDCs) CDMO Service total market, 2019-2030, (USD Million)
Global Peptide-Drug Conjugates(PDCs) CDMO Service total market by region & country, CAGR, 2019-2030, (USD Million)
U.S. VS China: Peptide-Drug Conjugates(PDCs) CDMO Service total market, key domestic companies, and share, (USD Million)
Global Peptide-Drug Conjugates(PDCs) CDMO Service revenue by player, revenue and market share 2019-2024, (USD Million)
Global Peptide-Drug Conjugates(PDCs) CDMO Service total market by Type, CAGR, 2019-2030, (USD Million)
Global Peptide-Drug Conjugates(PDCs) CDMO Service total market by Application, CAGR, 2019-2030, (USD Million)
This report profiles major players in the global Peptide-Drug Conjugates(PDCs) CDMO Service market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include WUXIAPP, Medicilon, Creative Peptides, Peptistar, BOCSCI Inc, HUATENG PHARMA, CPC Scientific Inc, Porton, VIVA Biotech, Taichu Group, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Peptide-Drug Conjugates(PDCs) CDMO Service market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2019-2030 by year with 2023 as the base year, 2024 as the estimate year, and 2025-2030 as the forecast year.

Global Peptide-Drug Conjugates(PDCs) CDMO Service Market, By Region:
    United States
    China
    Europe
    Japan
    South Korea
    ASEAN
    India
    Rest of World

Global Peptide-Drug Conjugates(PDCs) CDMO Service Market, Segmentation by Type
    Therapeutic
    Diagnostic

Global Peptide-Drug Conjugates(PDCs) CDMO Service Market, Segmentation by Application:
    SME Pharmaceutical Company
    Large Pharmaceutical Company

Companies Profiled:
    WUXIAPP
    Medicilon
    Creative Peptides
    Peptistar
    BOCSCI Inc
    HUATENG PHARMA
    CPC Scientific Inc
    Porton
    VIVA Biotech
    Taichu Group
    PharosGen
    CENTER LABORATORIES, INC
    JIUZHOU Pharmaceutical

Key Questions Answered
1. How big is the global Peptide-Drug Conjugates(PDCs) CDMO Service market?
2. What is the demand of the global Peptide-Drug Conjugates(PDCs) CDMO Service market?
3. What is the year over year growth of the global Peptide-Drug Conjugates(PDCs) CDMO Service market?
4. What is the total value of the global Peptide-Drug Conjugates(PDCs) CDMO Service market?
5. Who are the Major Players in the global Peptide-Drug Conjugates(PDCs) CDMO Service market?
6. What are the growth factors driving the market demand?

Table of Contents

1 Supply Summary
    1.1 Peptide-Drug Conjugates(PDCs) CDMO Service Introduction
    1.2 World Peptide-Drug Conjugates(PDCs) CDMO Service Market Size & Forecast (2019 & 2023 & 2030)
    1.3 World Peptide-Drug Conjugates(PDCs) CDMO Service Total Market by Region (by Headquarter Location)
        1.3.1 World Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Region (2019-2030), (by Headquarter Location)
        1.3.2 United States Based Company Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (2019-2030)
        1.3.3 China Based Company Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (2019-2030)
        1.3.4 Europe Based Company Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (2019-2030)
        1.3.5 Japan Based Company Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (2019-2030)
        1.3.6 South Korea Based Company Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (2019-2030)
        1.3.7 ASEAN Based Company Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (2019-2030)
        1.3.8 India Based Company Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (2019-2030)
    1.4 Market Drivers, Restraints and Trends
        1.4.1 Peptide-Drug Conjugates(PDCs) CDMO Service Market Drivers
        1.4.2 Factors Affecting Demand
        1.4.3 Major Market Trends

2 Demand Summary
    2.1 World Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value (2019-2030)
    2.2 World Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value by Region
        2.2.1 World Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value by Region (2019-2024)
        2.2.2 World Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value Forecast by Region (2025-2030)
    2.3 United States Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value (2019-2030)
    2.4 China Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value (2019-2030)
    2.5 Europe Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value (2019-2030)
    2.6 Japan Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value (2019-2030)
    2.7 South Korea Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value (2019-2030)
    2.8 ASEAN Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value (2019-2030)
    2.9 India Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value (2019-2030)

3 World Peptide-Drug Conjugates(PDCs) CDMO Service Companies Competitive Analysis
    3.1 World Peptide-Drug Conjugates(PDCs) CDMO Service Revenue by Player (2019-2024)
    3.2 Industry Rank and Concentration Rate (CR)
        3.2.1 Global Peptide-Drug Conjugates(PDCs) CDMO Service Industry Rank of Major Players
        3.2.2 Global Concentration Ratios (CR4) for Peptide-Drug Conjugates(PDCs) CDMO Service in 2023
        3.2.3 Global Concentration Ratios (CR8) for Peptide-Drug Conjugates(PDCs) CDMO Service in 2023
    3.3 Peptide-Drug Conjugates(PDCs) CDMO Service Company Evaluation Quadrant
    3.4 Peptide-Drug Conjugates(PDCs) CDMO Service Market: Overall Company Footprint Analysis
        3.4.1 Peptide-Drug Conjugates(PDCs) CDMO Service Market: Region Footprint
        3.4.2 Peptide-Drug Conjugates(PDCs) CDMO Service Market: Company Product Type Footprint
        3.4.3 Peptide-Drug Conjugates(PDCs) CDMO Service Market: Company Product Application Footprint
    3.5 Competitive Environment
        3.5.1 Historical Structure of the Industry
        3.5.2 Barriers of Market Entry
        3.5.3 Factors of Competition
    3.6 Mergers & Acquisitions Activity

4 United States VS China VS Rest of World (by Headquarter Location)
    4.1 United States VS China: Peptide-Drug Conjugates(PDCs) CDMO Service Revenue Comparison (by Headquarter Location)
        4.1.1 United States VS China: Peptide-Drug Conjugates(PDCs) CDMO Service Revenue Comparison (2019 & 2023 & 2030) (by Headquarter Location)
        4.1.2 United States VS China: Peptide-Drug Conjugates(PDCs) CDMO Service Revenue Market Share Comparison (2019 & 2023 & 2030)
    4.2 United States Based Companies VS China Based Companies: Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value Comparison
        4.2.1 United States VS China: Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value Comparison (2019 & 2023 & 2030)
        4.2.2 United States VS China: Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value Market Share Comparison (2019 & 2023 & 2030)
    4.3 United States Based Peptide-Drug Conjugates(PDCs) CDMO Service Companies and Market Share, 2019-2024
        4.3.1 United States Based Peptide-Drug Conjugates(PDCs) CDMO Service Companies, Headquarters (States, Country)
        4.3.2 United States Based Companies Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, (2019-2024)
    4.4 China Based Companies Peptide-Drug Conjugates(PDCs) CDMO Service Revenue and Market Share, 2019-2024
        4.4.1 China Based Peptide-Drug Conjugates(PDCs) CDMO Service Companies, Company Headquarters (Province, Country)
        4.4.2 China Based Companies Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, (2019-2024)
    4.5 Rest of World Based Peptide-Drug Conjugates(PDCs) CDMO Service Companies and Market Share, 2019-2024
        4.5.1 Rest of World Based Peptide-Drug Conjugates(PDCs) CDMO Service Companies, Headquarters (Province, Country)
        4.5.2 Rest of World Based Companies Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (2019-2024)

5 Market Analysis by Type
    5.1 World Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Overview by Type: 2019 VS 2023 VS 2030
    5.2 Segment Introduction by Type
        5.2.1 Therapeutic
        5.2.2 Diagnostic
    5.3 Market Segment by Type
        5.3.1 World Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Type (2019-2024)
        5.3.2 World Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Type (2025-2030)
        5.3.3 World Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Market Share by Type (2025-2030)

6 Market Analysis by Application
    6.1 World Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Overview by Application: 2019 VS 2023 VS 2030
    6.2 Segment Introduction by Application
        6.2.1 SME Pharmaceutical Company
        6.2.2 Large Pharmaceutical Company
    6.3 Market Segment by Application
        6.3.1 World Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Application (2019-2024)
        6.3.2 World Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Application (2025-2030)
        6.3.3 World Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Market Share by Application (2019-2030)

7 Company Profiles
    7.1 WUXIAPP
        7.1.1 WUXIAPP Details
        7.1.2 WUXIAPP Major Business
        7.1.3 WUXIAPP Peptide-Drug Conjugates(PDCs) CDMO Service Product and Services
        7.1.4 WUXIAPP Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross Margin and Market Share (2019-2024)
        7.1.5 WUXIAPP Recent Developments/Updates
        7.1.6 WUXIAPP Competitive Strengths & Weaknesses
    7.2 Medicilon
        7.2.1 Medicilon Details
        7.2.2 Medicilon Major Business
        7.2.3 Medicilon Peptide-Drug Conjugates(PDCs) CDMO Service Product and Services
        7.2.4 Medicilon Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross Margin and Market Share (2019-2024)
        7.2.5 Medicilon Recent Developments/Updates
        7.2.6 Medicilon Competitive Strengths & Weaknesses
    7.3 Creative Peptides
        7.3.1 Creative Peptides Details
        7.3.2 Creative Peptides Major Business
        7.3.3 Creative Peptides Peptide-Drug Conjugates(PDCs) CDMO Service Product and Services
        7.3.4 Creative Peptides Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross Margin and Market Share (2019-2024)
        7.3.5 Creative Peptides Recent Developments/Updates
        7.3.6 Creative Peptides Competitive Strengths & Weaknesses
    7.4 Peptistar
        7.4.1 Peptistar Details
        7.4.2 Peptistar Major Business
        7.4.3 Peptistar Peptide-Drug Conjugates(PDCs) CDMO Service Product and Services
        7.4.4 Peptistar Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross Margin and Market Share (2019-2024)
        7.4.5 Peptistar Recent Developments/Updates
        7.4.6 Peptistar Competitive Strengths & Weaknesses
    7.5 BOCSCI Inc
        7.5.1 BOCSCI Inc Details
        7.5.2 BOCSCI Inc Major Business
        7.5.3 BOCSCI Inc Peptide-Drug Conjugates(PDCs) CDMO Service Product and Services
        7.5.4 BOCSCI Inc Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross Margin and Market Share (2019-2024)
        7.5.5 BOCSCI Inc Recent Developments/Updates
        7.5.6 BOCSCI Inc Competitive Strengths & Weaknesses
    7.6 HUATENG PHARMA
        7.6.1 HUATENG PHARMA Details
        7.6.2 HUATENG PHARMA Major Business
        7.6.3 HUATENG PHARMA Peptide-Drug Conjugates(PDCs) CDMO Service Product and Services
        7.6.4 HUATENG PHARMA Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross Margin and Market Share (2019-2024)
        7.6.5 HUATENG PHARMA Recent Developments/Updates
        7.6.6 HUATENG PHARMA Competitive Strengths & Weaknesses
    7.7 CPC Scientific Inc
        7.7.1 CPC Scientific Inc Details
        7.7.2 CPC Scientific Inc Major Business
        7.7.3 CPC Scientific Inc Peptide-Drug Conjugates(PDCs) CDMO Service Product and Services
        7.7.4 CPC Scientific Inc Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross Margin and Market Share (2019-2024)
        7.7.5 CPC Scientific Inc Recent Developments/Updates
        7.7.6 CPC Scientific Inc Competitive Strengths & Weaknesses
    7.8 Porton
        7.8.1 Porton Details
        7.8.2 Porton Major Business
        7.8.3 Porton Peptide-Drug Conjugates(PDCs) CDMO Service Product and Services
        7.8.4 Porton Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross Margin and Market Share (2019-2024)
        7.8.5 Porton Recent Developments/Updates
        7.8.6 Porton Competitive Strengths & Weaknesses
    7.9 VIVA Biotech
        7.9.1 VIVA Biotech Details
        7.9.2 VIVA Biotech Major Business
        7.9.3 VIVA Biotech Peptide-Drug Conjugates(PDCs) CDMO Service Product and Services
        7.9.4 VIVA Biotech Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross Margin and Market Share (2019-2024)
        7.9.5 VIVA Biotech Recent Developments/Updates
        7.9.6 VIVA Biotech Competitive Strengths & Weaknesses
    7.10 Taichu Group
        7.10.1 Taichu Group Details
        7.10.2 Taichu Group Major Business
        7.10.3 Taichu Group Peptide-Drug Conjugates(PDCs) CDMO Service Product and Services
        7.10.4 Taichu Group Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross Margin and Market Share (2019-2024)
        7.10.5 Taichu Group Recent Developments/Updates
        7.10.6 Taichu Group Competitive Strengths & Weaknesses
    7.11 PharosGen
        7.11.1 PharosGen Details
        7.11.2 PharosGen Major Business
        7.11.3 PharosGen Peptide-Drug Conjugates(PDCs) CDMO Service Product and Services
        7.11.4 PharosGen Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross Margin and Market Share (2019-2024)
        7.11.5 PharosGen Recent Developments/Updates
        7.11.6 PharosGen Competitive Strengths & Weaknesses
    7.12 CENTER LABORATORIES, INC
        7.12.1 CENTER LABORATORIES, INC Details
        7.12.2 CENTER LABORATORIES, INC Major Business
        7.12.3 CENTER LABORATORIES, INC Peptide-Drug Conjugates(PDCs) CDMO Service Product and Services
        7.12.4 CENTER LABORATORIES, INC Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross Margin and Market Share (2019-2024)
        7.12.5 CENTER LABORATORIES, INC Recent Developments/Updates
        7.12.6 CENTER LABORATORIES, INC Competitive Strengths & Weaknesses
    7.13 JIUZHOU Pharmaceutical
        7.13.1 JIUZHOU Pharmaceutical Details
        7.13.2 JIUZHOU Pharmaceutical Major Business
        7.13.3 JIUZHOU Pharmaceutical Peptide-Drug Conjugates(PDCs) CDMO Service Product and Services
        7.13.4 JIUZHOU Pharmaceutical Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross Margin and Market Share (2019-2024)
        7.13.5 JIUZHOU Pharmaceutical Recent Developments/Updates
        7.13.6 JIUZHOU Pharmaceutical Competitive Strengths & Weaknesses

8 Industry Chain Analysis
    8.1 Peptide-Drug Conjugates(PDCs) CDMO Service Industry Chain
    8.2 Peptide-Drug Conjugates(PDCs) CDMO Service Upstream Analysis
    8.3 Peptide-Drug Conjugates(PDCs) CDMO Service Midstream Analysis
    8.4 Peptide-Drug Conjugates(PDCs) CDMO Service Downstream Analysis

9 Research Findings and Conclusion

10 Appendix
    10.1 Methodology
    10.2 Research Process and Data Source
    10.3 Disclaimer

Table of Figures

List of Tables
 Table 1. World Peptide-Drug Conjugates(PDCs) CDMO Service Revenue by Region (2019, 2023 and 2030) & (USD Million), (by Headquarter Location)
 Table 2. World Peptide-Drug Conjugates(PDCs) CDMO Service Revenue by Region (2019-2024) & (USD Million), (by Headquarter Location)
 Table 3. World Peptide-Drug Conjugates(PDCs) CDMO Service Revenue by Region (2025-2030) & (USD Million), (by Headquarter Location)
 Table 4. World Peptide-Drug Conjugates(PDCs) CDMO Service Revenue Market Share by Region (2019-2024), (by Headquarter Location)
 Table 5. World Peptide-Drug Conjugates(PDCs) CDMO Service Revenue Market Share by Region (2025-2030), (by Headquarter Location)
 Table 6. Major Market Trends
 Table 7. World Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value Growth Rate Forecast by Region (2019 & 2023 & 2030) & (USD Million)
 Table 8. World Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value by Region (2019-2024) & (USD Million)
 Table 9. World Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value Forecast by Region (2025-2030) & (USD Million)
 Table 10. World Peptide-Drug Conjugates(PDCs) CDMO Service Revenue by Player (2019-2024) & (USD Million)
 Table 11. Revenue Market Share of Key Peptide-Drug Conjugates(PDCs) CDMO Service Players in 2023
 Table 12. World Peptide-Drug Conjugates(PDCs) CDMO Service Industry Rank of Major Player, Based on Revenue in 2023
 Table 13. Global Peptide-Drug Conjugates(PDCs) CDMO Service Company Evaluation Quadrant
 Table 14. Head Office of Key Peptide-Drug Conjugates(PDCs) CDMO Service Players
 Table 15. Peptide-Drug Conjugates(PDCs) CDMO Service Market: Company Product Type Footprint
 Table 16. Peptide-Drug Conjugates(PDCs) CDMO Service Market: Company Product Application Footprint
 Table 17. Peptide-Drug Conjugates(PDCs) CDMO Service Mergers & Acquisitions Activity
 Table 18. United States VS China Peptide-Drug Conjugates(PDCs) CDMO Service Revenue Comparison, (2019 & 2023 & 2030) & (USD Million)
 Table 19. United States VS China Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value Comparison, (2019 & 2023 & 2030) & (USD Million)
 Table 20. United States Based Peptide-Drug Conjugates(PDCs) CDMO Service Companies, Headquarters (States, Country)
 Table 21. United States Based Companies Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, (2019-2024) & (USD Million)
 Table 22. United States Based Companies Peptide-Drug Conjugates(PDCs) CDMO Service Revenue Market Share (2019-2024)
 Table 23. China Based Peptide-Drug Conjugates(PDCs) CDMO Service Companies, Headquarters (Province, Country)
 Table 24. China Based Companies Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, (2019-2024) & (USD Million)
 Table 25. China Based Companies Peptide-Drug Conjugates(PDCs) CDMO Service Revenue Market Share (2019-2024)
 Table 26. Rest of World Based Peptide-Drug Conjugates(PDCs) CDMO Service Companies, Headquarters (Province, Country)
 Table 27. Rest of World Based Companies Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (2019-2024) & (USD Million)
 Table 28. Rest of World Based Companies Peptide-Drug Conjugates(PDCs) CDMO Service Revenue Market Share (2019-2024)
 Table 29. World Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Type, (USD Million), 2019 & 2023 & 2030
 Table 30. World Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Value by Type (2019-2024) & (USD Million)
 Table 31. World Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Type (2025-2030) & (USD Million)
 Table 32. World Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Application, (USD Million), 2019 & 2023 & 2030
 Table 33. World Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Application (2019-2024) & (USD Million)
 Table 34. World Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Application (2025-2030) & (USD Million)
 Table 35. WUXIAPP Basic Information, Manufacturing Base and Competitors
 Table 36. WUXIAPP Major Business
 Table 37. WUXIAPP Peptide-Drug Conjugates(PDCs) CDMO Service Product and Services
 Table 38. WUXIAPP Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
 Table 39. WUXIAPP Recent Developments/Updates
 Table 40. WUXIAPP Competitive Strengths & Weaknesses
 Table 41. Medicilon Basic Information, Manufacturing Base and Competitors
 Table 42. Medicilon Major Business
 Table 43. Medicilon Peptide-Drug Conjugates(PDCs) CDMO Service Product and Services
 Table 44. Medicilon Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
 Table 45. Medicilon Recent Developments/Updates
 Table 46. Medicilon Competitive Strengths & Weaknesses
 Table 47. Creative Peptides Basic Information, Manufacturing Base and Competitors
 Table 48. Creative Peptides Major Business
 Table 49. Creative Peptides Peptide-Drug Conjugates(PDCs) CDMO Service Product and Services
 Table 50. Creative Peptides Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
 Table 51. Creative Peptides Recent Developments/Updates
 Table 52. Creative Peptides Competitive Strengths & Weaknesses
 Table 53. Peptistar Basic Information, Manufacturing Base and Competitors
 Table 54. Peptistar Major Business
 Table 55. Peptistar Peptide-Drug Conjugates(PDCs) CDMO Service Product and Services
 Table 56. Peptistar Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
 Table 57. Peptistar Recent Developments/Updates
 Table 58. Peptistar Competitive Strengths & Weaknesses
 Table 59. BOCSCI Inc Basic Information, Manufacturing Base and Competitors
 Table 60. BOCSCI Inc Major Business
 Table 61. BOCSCI Inc Peptide-Drug Conjugates(PDCs) CDMO Service Product and Services
 Table 62. BOCSCI Inc Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
 Table 63. BOCSCI Inc Recent Developments/Updates
 Table 64. BOCSCI Inc Competitive Strengths & Weaknesses
 Table 65. HUATENG PHARMA Basic Information, Manufacturing Base and Competitors
 Table 66. HUATENG PHARMA Major Business
 Table 67. HUATENG PHARMA Peptide-Drug Conjugates(PDCs) CDMO Service Product and Services
 Table 68. HUATENG PHARMA Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
 Table 69. HUATENG PHARMA Recent Developments/Updates
 Table 70. HUATENG PHARMA Competitive Strengths & Weaknesses
 Table 71. CPC Scientific Inc Basic Information, Manufacturing Base and Competitors
 Table 72. CPC Scientific Inc Major Business
 Table 73. CPC Scientific Inc Peptide-Drug Conjugates(PDCs) CDMO Service Product and Services
 Table 74. CPC Scientific Inc Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
 Table 75. CPC Scientific Inc Recent Developments/Updates
 Table 76. CPC Scientific Inc Competitive Strengths & Weaknesses
 Table 77. Porton Basic Information, Manufacturing Base and Competitors
 Table 78. Porton Major Business
 Table 79. Porton Peptide-Drug Conjugates(PDCs) CDMO Service Product and Services
 Table 80. Porton Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
 Table 81. Porton Recent Developments/Updates
 Table 82. Porton Competitive Strengths & Weaknesses
 Table 83. VIVA Biotech Basic Information, Manufacturing Base and Competitors
 Table 84. VIVA Biotech Major Business
 Table 85. VIVA Biotech Peptide-Drug Conjugates(PDCs) CDMO Service Product and Services
 Table 86. VIVA Biotech Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
 Table 87. VIVA Biotech Recent Developments/Updates
 Table 88. VIVA Biotech Competitive Strengths & Weaknesses
 Table 89. Taichu Group Basic Information, Manufacturing Base and Competitors
 Table 90. Taichu Group Major Business
 Table 91. Taichu Group Peptide-Drug Conjugates(PDCs) CDMO Service Product and Services
 Table 92. Taichu Group Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
 Table 93. Taichu Group Recent Developments/Updates
 Table 94. Taichu Group Competitive Strengths & Weaknesses
 Table 95. PharosGen Basic Information, Manufacturing Base and Competitors
 Table 96. PharosGen Major Business
 Table 97. PharosGen Peptide-Drug Conjugates(PDCs) CDMO Service Product and Services
 Table 98. PharosGen Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
 Table 99. PharosGen Recent Developments/Updates
 Table 100. PharosGen Competitive Strengths & Weaknesses
 Table 101. CENTER LABORATORIES, INC Basic Information, Manufacturing Base and Competitors
 Table 102. CENTER LABORATORIES, INC Major Business
 Table 103. CENTER LABORATORIES, INC Peptide-Drug Conjugates(PDCs) CDMO Service Product and Services
 Table 104. CENTER LABORATORIES, INC Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
 Table 105. CENTER LABORATORIES, INC Recent Developments/Updates
 Table 106. CENTER LABORATORIES, INC Competitive Strengths & Weaknesses
 Table 107. JIUZHOU Pharmaceutical Basic Information, Manufacturing Base and Competitors
 Table 108. JIUZHOU Pharmaceutical Major Business
 Table 109. JIUZHOU Pharmaceutical Peptide-Drug Conjugates(PDCs) CDMO Service Product and Services
 Table 110. JIUZHOU Pharmaceutical Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
 Table 111. JIUZHOU Pharmaceutical Recent Developments/Updates
 Table 112. JIUZHOU Pharmaceutical Competitive Strengths & Weaknesses
 Table 113. Global Key Players of Peptide-Drug Conjugates(PDCs) CDMO Service Upstream (Raw Materials)
 Table 114. Global Peptide-Drug Conjugates(PDCs) CDMO Service Typical Customers


List of Figures
 Figure 1. Peptide-Drug Conjugates(PDCs) CDMO Service Picture
 Figure 2. World Peptide-Drug Conjugates(PDCs) CDMO Service Total Revenue: 2019 & 2023 & 2030, (USD Million)
 Figure 3. World Peptide-Drug Conjugates(PDCs) CDMO Service Total Revenue (2019-2030) & (USD Million)
 Figure 4. World Peptide-Drug Conjugates(PDCs) CDMO Service Revenue by Region (2019, 2023 and 2030) & (USD Million), (by Headquarter Location)
 Figure 5. World Peptide-Drug Conjugates(PDCs) CDMO Service Revenue Market Share by Region (2019-2030), (by Headquarter Location)
 Figure 6. United States Based Company Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (2019-2030) & (USD Million)
 Figure 7. China Based Company Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (2019-2030) & (USD Million)
 Figure 8. Europe Based Company Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (2019-2030) & (USD Million)
 Figure 9. Japan Based Company Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (2019-2030) & (USD Million)
 Figure 10. South Korea Based Company Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (2019-2030) & (USD Million)
 Figure 11. ASEAN Based Company Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (2019-2030) & (USD Million)
 Figure 12. India Based Company Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (2019-2030) & (USD Million)
 Figure 13. Peptide-Drug Conjugates(PDCs) CDMO Service Market Drivers
 Figure 14. Factors Affecting Demand
 Figure 15. World Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value (2019-2030) & (USD Million)
 Figure 16. World Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value Market Share by Region (2019-2030)
 Figure 17. United States Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value (2019-2030) & (USD Million)
 Figure 18. China Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value (2019-2030) & (USD Million)
 Figure 19. Europe Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value (2019-2030) & (USD Million)
 Figure 20. Japan Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value (2019-2030) & (USD Million)
 Figure 21. South Korea Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value (2019-2030) & (USD Million)
 Figure 22. ASEAN Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value (2019-2030) & (USD Million)
 Figure 23. India Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value (2019-2030) & (USD Million)
 Figure 24. Producer Shipments of Peptide-Drug Conjugates(PDCs) CDMO Service by Player Revenue ($MM) and Market Share (%): 2023
 Figure 25. Global Four-firm Concentration Ratios (CR4) for Peptide-Drug Conjugates(PDCs) CDMO Service Markets in 2023
 Figure 26. Global Four-firm Concentration Ratios (CR8) for Peptide-Drug Conjugates(PDCs) CDMO Service Markets in 2023
 Figure 27. United States VS China: Peptide-Drug Conjugates(PDCs) CDMO Service Revenue Market Share Comparison (2019 & 2023 & 2030)
 Figure 28. United States VS China: Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value Market Share Comparison (2019 & 2023 & 2030)
 Figure 29. World Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Type, (USD Million), 2019 & 2023 & 2030
 Figure 30. World Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Market Share by Type in 2023
 Figure 31. Therapeutic
 Figure 32. Diagnostic
 Figure 33. World Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Market Share by Type (2019-2030)
 Figure 34. World Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Application, (USD Million), 2019 & 2023 & 2030
 Figure 35. World Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Market Share by Application in 2023
 Figure 36. SME Pharmaceutical Company
 Figure 37. Large Pharmaceutical Company
 Figure 38. World Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Market Share by Application (2019-2030)
 Figure 39. Peptide-Drug Conjugates(PDCs) CDMO Service Industrial Chain
 Figure 40. Methodology
 Figure 41. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Companies Mentioned

WUXIAPP
Medicilon
Creative Peptides
Peptistar
BOCSCI Inc
HUATENG PHARMA
CPC Scientific Inc
Porton
VIVA Biotech
Taichu Group
PharosGen
CENTER LABORATORIES, INC
JIUZHOU Pharmaceutical

Related Reports

Global Peptide-Drug Conjugates(PDCs) CDMO Service Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Global Peptide-Drug Conjugates(PDCs) CDMO Service Market 2024 by Company, Regions, Type and Application, Forecast to 2030

date 11 Oct 2024

date Medical Care

Peptide-drug conjugates (PDCs) consist of a cytotoxic payload, a homing peptide, and a linker between the peptide and the cytotoxic payload. Following antibody-drug conjugates, they are the next generation of targeted therapeutics with enhanced cell permeability and better drug selectivity. They offer excellent opportunities for targeting cancer, metabolic diseases, and more. Although the potential is huge, development challenges such as poor stability, poor targeting, and potential payload toxicity may slow down preclinical and clinical development processes. CDMO services refer to pharmaceutical companies and biotechnology companies outsourcing the research and development and production of their drugs or biologics to professional CDMO companies. These CDMO companies provide a range of services, including but not limited to drug synthesis, chemical and biological analysis, formulation development, clinical production, and commercial production. The core of CDMO services lies in its customization and specialization capabilities, which can meet the specific needs of different customers at different stages.

Product Tags

Peptide-Drug Conjugates(PDCs) CDMO Service

Organ Rejection Prophylaxis Treatment

Biologics Analytical Services

Purchase Options

Single User License

USD4480.00

Multi User License

USD6720.00

Corporate Users License

USD8960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>